Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
RFK Jr. Spokesman Resigns Over Trump Administration’s Flavored E-Cigarette Policy 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
Eli Lilly announced that its experimental weight-loss pill, orforglipron, meets most of the criteria for the U.S. Food and Drug Administration’s (FDA) new national priority voucher, positioning it for potentially accelerated approval. The pharmaceutical giant plans to submit its application this quarter, with the FDA set to determine the review timeline. Under the new program, qualifying drugs can receive review periods as short as one to two months, compared to the usual ten to twelve.
The criteria for the voucher program include innovation, addressing unmet medical needs, and supporting U.S. manufacturing—three areas in which Lilly claims strong alignment. The GLP-1 pill demonstrated significant effectiveness in late-stage trials, helping patients lose 12.4% of body weight, and Lilly has invested heavily in domestic production facilities to meet future demand.
The FDA recently announced the first nine recipients of this voucher, including Merck KGaA, Sanofi, and Regeneron, signaling heightened competition in the accelerated drug review space.
Alongside regulatory progress, Lilly reported a major earnings beat, driven by surging international demand for its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound. Third-quarter earnings reached $7.02 per share, well above analyst expectations of $5.69. Sales of Mounjaro totaled $6.5 billion, while Zepbound brought in $3.6 billion, both surpassing projections.
Lilly raised its full-year profit outlook to between $23.00 and $23.70 per share, up from previous guidance. The company now expects annual revenue between $63 billion and $63.5 billion. Analysts credit strong overseas demand and consistent consumer interest in weight-loss therapies for Lilly’s sustained growth, solidifying its leadership position against rival Novo Nordisk. As the global market for obesity drugs accelerates toward an estimated $150 billion by decade’s end, Eli Lilly continues to dominate the sector with robust innovation and expanding market share.
